Last reviewed · How we verify

Ethambutol Oral Product

Wits Health Consortium (Pty) Ltd · Phase 3 active Small molecule

Ethambutol Oral Product is a Antituberculous agent Small molecule drug developed by Wits Health Consortium (Pty) Ltd. It is currently in Phase 3 development for Tuberculosis (pulmonary and extrapulmonary), Mycobacterium avium complex (MAC) infection.

Ethambutol inhibits mycobacterial arabinosyl transferases, disrupting the synthesis of the mycobacterial cell wall component arabinogalactan.

Ethambutol inhibits mycobacterial arabinosyl transferases, disrupting the synthesis of the mycobacterial cell wall component arabinogalactan. Used for Tuberculosis (pulmonary and extrapulmonary), Mycobacterium avium complex (MAC) infection.

At a glance

Generic nameEthambutol Oral Product
SponsorWits Health Consortium (Pty) Ltd
Drug classAntituberculous agent
TargetArabinosyl transferases (EmbA, EmbB, EmbC)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Ethambutol is a first-line antituberculous agent that selectively inhibits enzymes involved in arabinogalactan biosynthesis in mycobacteria. By disrupting cell wall integrity, it is bacteriostatic against Mycobacterium tuberculosis and other mycobacterial species. It is typically used in combination with other antituberculous drugs to prevent resistance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ethambutol Oral Product

What is Ethambutol Oral Product?

Ethambutol Oral Product is a Antituberculous agent drug developed by Wits Health Consortium (Pty) Ltd, indicated for Tuberculosis (pulmonary and extrapulmonary), Mycobacterium avium complex (MAC) infection.

How does Ethambutol Oral Product work?

Ethambutol inhibits mycobacterial arabinosyl transferases, disrupting the synthesis of the mycobacterial cell wall component arabinogalactan.

What is Ethambutol Oral Product used for?

Ethambutol Oral Product is indicated for Tuberculosis (pulmonary and extrapulmonary), Mycobacterium avium complex (MAC) infection.

Who makes Ethambutol Oral Product?

Ethambutol Oral Product is developed by Wits Health Consortium (Pty) Ltd (see full Wits Health Consortium (Pty) Ltd pipeline at /company/wits-health-consortium-pty-ltd).

What drug class is Ethambutol Oral Product in?

Ethambutol Oral Product belongs to the Antituberculous agent class. See all Antituberculous agent drugs at /class/antituberculous-agent.

What development phase is Ethambutol Oral Product in?

Ethambutol Oral Product is in Phase 3.

What are the side effects of Ethambutol Oral Product?

Common side effects of Ethambutol Oral Product include Optic neuritis, Color blindness (red-green), Peripheral neuropathy, Hyperuricemia, Gastrointestinal disturbance, Headache.

What does Ethambutol Oral Product target?

Ethambutol Oral Product targets Arabinosyl transferases (EmbA, EmbB, EmbC) and is a Antituberculous agent.

Related